Advances in Cardiology Research and Treatment

The chapter explores the evolution of coronary artery disease terminology, the efficacy of empagliflows in heart failure therapy, and the positive outcomes of trials with SGLT2 inhibitors. It discusses the benefits of SGLT2 inhibitors in heart failure and CKD treatment, the safety of ACE inhibitors and ARBs in COVID-19 patients, and introduces new treatments for cardiac conditions like Mavacamptin for hypertrophic obstructive cardiomyopathy. Furthermore, it highlights trials emphasizing rate control, anti-coagulation, and early discharge with home management for pulmonary embolisms, along with the potential of AI in diagnosing cardiac conditions.